Screening for primary open-angle glaucoma in the primary care setting: An update for the US Preventive Services Task Force

Annals of Family Medicine

Volumn 3, Issue 2, 2005, Pages 167-170

  Fleming, Craig ^a,c   Whitlock, Evelyn P ^a   Beil, Tracy ^a   Smit, Barbara ^a   Harris, Russell P ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

AHRQ; Evidence based medicine; Glaucoma, open angle; Intraocular hypertension; Mass screening; Review publication type

Indexed keywords

BLINDNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FAMILY MEDICINE; FUNCTIONAL ASSESSMENT; HUMAN; INTRAOCULAR PRESSURE; MASS SCREENING; OPEN ANGLE GLAUCOMA; PRESSURE MEASUREMENT; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SCREENING; VISUAL FIELD;

GLAUCOMA, OPEN-ANGLE; HUMANS; PRIMARY HEALTH CARE; UNITED STATES;

EID: 16444375302     PISSN: 15441709     EISSN: None     Source Type: Journal    
DOI: 10.1370/afm.293     Document Type: Review

References (24)

1. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.
2. Quigley HA, Tielsch JM, Katz J, Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol. 1996;122:355-363.
3. Quigley HA. Open-angle glaucoma. N Engl J Med. 1993;328:1097-1106.
4. American Academy of Ophthalmology. Preferred Practice Pattern. Primary Open-Angle Glaucoma. San Francisco, Calif: American Academy of Ophthalmology; 2003.
5. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266:369-374.
6. U.S. Preventive Services Task Force. Screening for glaucoma. In: DiGuiseppi C, Atkins D, Woolf SH, Kamerow DB, eds. Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996:383-391.
7. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35.
8. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991;134:1102-1110.
9. Quigley HA, Katz J, Derick RJ, Gilbert D, Sommer A. An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. Ophthalmology. 1992;99:19-28.
10. Ellish NJ, Higginbotham EJ. Evaluating a visual field screening test for glaucoma: how the choice of the gold standard affects the validity of the test. Ophthalmic Epidemiol. 2001;8:297-307.
11. American Academy of Opthamology. Comprehensive Adult Medical Eye Evaluation. San Francisco, Calif; 2000.
12. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. J Arch Ophthalmol. 2002;120:701-713; discussion 829-730.
13. Robin AL, Frick KD, Katz J, Budenz D, Tielsch JM. The ocular hypertension treatment study: intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease? Arch Ophthalmol. 2004;122:376-378.
14. Jampel HD. We should treat fewer patients with elevated intraocular pressure now that we know the results of the ocular hypertension treatment study. Arch Ophthalmol. 2004;122:378-379.
15. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995;120:718-731.
16. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995;120:10-22.
17. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol. 2002;134:499-512.
18. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.
19. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
20. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487-497.
21. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498-505.
22. Katz J, Congdon N, Friedman DS. Methodological variations in estimating apparent progressive visual field loss in clinical trials of glaucoma treatment. Arch Ophthalmol. 1999;117:1137-1142.
23. Gutierrez P, Wilson MR, Johnson C, et al. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol. 1997;115:777-784.
24. Parrish RK, 2nd, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997;115:1447-1455.